Join

Compare · CI vs OPGN

CI vs OPGN

Side-by-side comparison of The Cigna Group (CI) and OpGen Inc. (OPGN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CI and OPGN operate in Medical Specialities (Health Care), so they compete in similar markets.
  • CI is the larger of the two at $77.37B, about 2016.4x OPGN ($38.4M).
  • CI has hit the wire 14 times in the past 4 weeks while OPGN has been quiet.
  • CI has more recent analyst coverage (25 ratings vs 0 for OPGN).
MetricCIOPGN
Company
The Cigna Group
OpGen Inc.
Price
$275.55-1.49%
$1.96-14.04%
Market cap
$77.37B
$38.4M
1M return
+1.90%
-
1Y return
-17.71%
-
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2015
News (4w)
14
0
Recent ratings
25
0
CI

The Cigna Group

Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

OPGN

OpGen Inc.

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is based in Rockville, Maryland.

Latest CI

Latest OPGN